Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03997370 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
A Phase 1 study of Malignant Solid Neoplasm, sponsored by NRG Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT03997370 is a Phase 1 study of Malignant Solid Neoplasm that is actively recruiting participants, run by NRG Oncology. The registered enrollment target is 350 participants, below the 1,139-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT03997370, a Phase 1 study of Malignant Solid Neoplasm, is actively recruiting participants, sponsored by NRG Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial studies how well iohexol works in helping doctors calculate the dose of carboplatin given to patients with cancer. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Understanding how to best calculate the dose of carboplatin given to patients with cancer may help doctors learn how to improve the use of carboplatin in the future.
Conditions Studied
Interventions
- DRUG Carboplatin
- PROCEDURE Biospecimen Collection
- DRUG Iohexol
Study Locations (20)
Colorado
- UCHealth University of Colorado Hospital - Aurora
- Poudre Valley Hospital - Fort Collins
- Cancer Care and Hematology-Fort Collins - Fort Collins
- UCHealth Greeley Hospital - Greeley
- Medical Center of the Rockies - Loveland
California
- UC San Diego Health System - Encinitas - Encinitas
- UC San Diego Moores Cancer Center - La Jolla
- University of California Davis Comprehensive Cancer Center - Sacramento
- UC San Diego Medical Center - Hillcrest - San Diego
Arizona
- University of Arizona Cancer Center-Orange Grove Campus - Tucson
- Banner University Medical Center - Tucson - Tucson
- University of Arizona Cancer Center-North Campus - Tucson
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- CARTI Cancer Center - Little Rock
- University of Arkansas for Medical Sciences - Little Rock
Connecticut
- Hartford Hospital - Hartford
- The Hospital of Central Connecticut - New Britain
Georgia
- Emory University Hospital Midtown - Atlanta
- Emory University Hospital/Winship Cancer Institute - Atlanta
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2020-01-15 |
| Est. Completion | 2028-02-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03997370
The ClinicalTrials.gov registry entry for NCT03997370 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,139-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (69% lower). The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT03997370 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Colorado, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03997370 about?
NCT03997370 is a clinical study titled "Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol". This trial studies how well iohexol works in helping doctors calculate the dose of carboplatin given to patients with cancer. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by ...
What is the current status of trial NCT03997370?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 350 participants. The study started on 2020-01-15. Estimated completion is 2028-02-06.
What conditions does trial NCT03997370 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm.
What interventions are being tested in trial NCT03997370?
The interventions under investigation include: Carboplatin (DRUG), Biospecimen Collection (PROCEDURE), Iohexol (DRUG).
Who is sponsoring clinical trial NCT03997370?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03997370 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
RECRUITING · Phase 1
-
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
RECRUITING · Phase 1
-
Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction
RECRUITING · Phase 1
-
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
RECRUITING · Phase 1
-
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.